Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1Neoplasms 1Lymphoma 1

Interventions

Paclitaxel 4pembrolizumab 2pazopanib 2Trastuzumab 2Sorafenib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Gefitinib 2Doxorubicin 2Cisplatin 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tremelimumab 1trametinib 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1mercaptoundecahydrododecaborate 1lenvatinib 1fosbretabulin 1efatutazone 1durvalumab 1dabrafenib 1crolibulin 1cabozantinib 1atezolizumab 1aldesleukin 1abemaciclib 1Taxes 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thyroid Carcinoma, Anaplastic × crolibulin × Clear all
NCT01240590 2017-04-10

A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
27 enrolled 15 charts
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡